A5027919779- Psoriasis: Treatment and Pathogenesis
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Gastrointestinal motility and disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Autoimmune Bullous Skin Diseases
- Congenital gastrointestinal and neural anomalies
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Pediatric health and respiratory diseases
- Cancer and Skin Lesions
- Rheumatoid Arthritis Research and Therapies
- Restraint-Related Deaths
- Parasitic Diseases Research and Treatment
- Nursing care and research
- Salivary Gland Tumors Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Entomological Studies and Ecology
- Breast Lesions and Carcinomas
- Spondyloarthritis Studies and Treatments
- Parvovirus B19 Infection Studies
- Anorectal Disease Treatments and Outcomes
- Spinal Dysraphism and Malformations
- Dermatology and Skin Diseases
- Skin and Cellular Biology Research
Hospital Arnau de Vilanova
2019-2021
Hospital de Sagunto
2014
Hospital Oncológico Docente "Conrado Benítez García"
2013
Hospital de Mataró
2007-2009
Induction of immune tolerance as therapeutic approach for autoimmune diseases constitutes a current research focal point. In this sense, we aimed to evaluate an altered peptide ligand (APL) induction peripheral in patients with rheumatoid arthritis (RA). A novel T-cell epitope from human heat-shock protein 60 (Hsp60), autoantigen involved the pathogenesis RA, was identified by bioinformatics tools and APL design starting epitope. We investigated ability inducing regulatory T cells (Treg...
T cells are involved in the pathogenesis of rheumatoid arthritis (RA). CD6 is a co-stimulatory molecule, predominantly expressed on lymphocytes, that has been linked to autoreactive responses. The purpose this study was evaluate safety, immunogenicity and preliminary efficacy itolizumab, humanized anti-CD6 monoclonal antibody, patients with active arthritis. Fifteen were enrolled phase I, open-label, dose-finding study. Five cohorts received weekly antibody monotherapy dose-range from 0.1...
Summary Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, 6-week monotherapy trial conducted rheumatoid arthritis (RA) patients. The current Phase I study evaluated the response for longer treatment 12 itolizumab intravenous doses subjects with active RA despite previous disease-modifying anti-rheumatic drug (DMARD) therapy. Twenty-one were enrolled into four dosage groups (0·1, 0·2,...
Rheumatoid arthritis is a systemic autoimmune disease mediated by T cells. Productive engagement of cell receptors major histocompatibility complex-peptide leads to proliferation, differentiation and the definition effector functions. Altered peptide ligands (APL) generated amino acid substitutions in antigenic have diverse effects on response. We predicted novel epitope from human heat-shock protein 60, an autoantigen involved pathogenesis rheumatoid arthritis. Three APLs were designed this...
Objectives: To report a case of response to ustekinumab in patient with severe psoriasis when adalimumab dose escalation fail.Case Description: A 35-year-old Caucasian male was diagnosed as having psoriasis. He started on methotrexate followed cyclosporine. Despite these treatments, the experienced an abrupt deterioration his [PASI 35]. The treatment adalimumab: initial 80mg by 40mg week 2. At 3 he continued 40mg/two weeks significant reduction After 8 months therapy, referred that effective...